Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) was the recipient of a significant decline in short interest in December. As of December 31st, there was short interest totalling 37,100 shares, a decline of 45.2% from the December 15th total of 67,700 shares. Based on an average daily trading volume, of 307,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 2.8% of the company’s stock are sold short.
Sonoma Pharmaceuticals Price Performance
Shares of Sonoma Pharmaceuticals stock traded up $0.02 on Tuesday, hitting $2.60. The company had a trading volume of 13,565 shares, compared to its average volume of 42,419. Sonoma Pharmaceuticals has a twelve month low of $2.44 and a twelve month high of $9.37. The stock has a 50-day moving average of $2.74 and a 200-day moving average of $2.10. The firm has a market capitalization of $3.48 million, a P/E ratio of -0.52 and a beta of 1.41.
Institutional Trading of Sonoma Pharmaceuticals
A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 1.95% of the stock is currently owned by institutional investors and hedge funds.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.
Further Reading
- Five stocks we like better than Sonoma Pharmaceuticals
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Investing In Preferred Stock vs. Common Stock
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Compound Interest and Why It Matters When Investing
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
